Analgin ampoules 50% 1ml. №10

active ingredient: 1 tablet contains metamizole sodium 500 mg;

excipients: sodium metabisulphite (E 223), Trilon B, sodium formaldehyde sulfoxylates, sodium hydroxide, water for injection.

Injection.

Basic physico-chemical properties: transparent colorless or yellowish solution.

Analgesics and antipyretics. Metamizole sodium. ATX code N02B B02.

Anesthetic, antipyretic, antispasmodic (acts on the smooth muscles of the urinary and biliary tract) means of the group of pyrazolone derivatives. The anti-inflammatory effect is weakly expressed.

The mechanism of action is due to the inhibition of cyclooxygenase, which leads to a decrease in the synthesis of prostaglandins, which cause the development of pain in the focus of inflammation, an increase in temperature and an increase in tissue permeability, as well as a violation of the conduction of pain extra and proprioceptive impulses, an increase in the excitability threshold of thalamic pain sensitivity centers, and an increase in heat transfer.

After administration, metamizole is hydrolyzed to an active metabolite (when administered intravenously, unchanged metamizole is found in blood plasma in small quantities). Communication of an active metabolite with proteins – 50-60%. Metabolized in the liver, excreted by the kidneys. Penetrates through the placental barrier and into breast milk.

Pain syndrome of low and medium intensity of various origin and localization (headache, toothache, burns, pain in the postoperative period, dysmenorrhea, arthralgia, neuralgia, radiculitis, myositis) hyperthermic syndrome, febrile conditions (with influenza, acute respiratory and other infections) renal and hepatic colic (in combination with antispasmodics).

Hypersensitivity to metamizole sodium, to other pyrazolone derivatives or other components of Analgin ampoules. Attacks of bronchial asthma caused by acetylsalicylic acid. Violation of hematopoiesis (agranulocytosis, cytostatic or infectious neutropenia). Liver and / or renal failure. Hereditary hemolytic anemia associated with deficiency of glucose-6-phosphate dehydrogenase. Suspicion of acute surgical pathology. Anemia, leukopenia. Kidney disease pyelonephritis, glomerulonephritis, including history. Do not administer to patients with systolic blood pressure below 100 mm Hg. Art. Polytrauma. Shock. Porfiry.